IP Library Granted Patent US 10,982,294
Granted Patent B2
US 10,982,294 · App. 15/366,147 · Granted Apr 20, 2021

Reagents and methods for detecting HCV

Inventors: Arejas Uzgiris (Berkeley, CA); Sunil Pandit (Danville, CA); Lance Palmer (Collierville, TN)
Assignee: Siemens Healthcare Diagnostics Inc.
C12Q1/707
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,982,294
App. No.
15/366,147
Granted
Apr 20, 2021
Kind
B2
Abstract

The present disclosure relates to oligonucleotide sequences for amplification primers and their use in performing nucleic acid amplifications of HCV, in particular regions that encode the NS3 polypeptide. In some embodiments the primers are used in nested PCR methods for the detection or sequencing of HCV NS3. The oligonucleotide sequences are also provided assembled as kits that can be used to amplify and detect or sequence HCV NS3.

Claims (37)

1. An amplification primer pair for amplifying a portion of a HCV NS3 1b genomic sequence consisting of a forward primer and a reverse primer, wherein:

the forward primer is selected from the group consisting of:

(i) the nucleic acid sequence of SEQ ID NO: 14 or an active fragment thereof, and

(ii) the nucleic acid sequence of SEQ ID NO: 15 or an active fragment thereof; and

the reverse primer is selected from the group consisting of:

(i) the nucleic acid sequence of SEQ ID NO: 16 or an active fragment thereof,

(ii) the nucleic acid sequence of SEQ ID NO: 19 or an active fragment thereof, and

(iii) the nucleic acid sequence of SEQ ID NO: 20 or an active fragment thereof;

wherein the forward primer and the reverse primer are deoxyribonucleic acid primers, and wherein an active fragment is 15 or more nucleotides in length.

2. A collection of primers for amplifying a portion of a HCV NS3 1b genomic sequence consisting of:

(i) a forward primer comprising the nucleic acid sequence of SEQ ID NO: 11 or an active fragment thereof,

(ii) a forward primer comprising the nucleic acid sequence of SEQ ID NO: 12 or an active fragment thereof,

(iii) a forward primer comprising the nucleic acid sequence of SEQ ID NO: 13 or an active fragment thereof,

(iv) a forward primer comprising the nucleic acid sequence of SEQ ID NO: 14 or an active fragment thereof,

(v) a forward primer comprising the nucleic acid sequence of SEQ ID NO: 15 or an active fragment thereof,

(vi) a reverse primer comprising the nucleic acid sequence of SEQ ID NO: 16 or an active fragment thereof,

(vii) a reverse primer comprising the nucleic acid sequence of SEQ ID NO: 17 or an active fragment thereof,

(viii) a reverse primer comprising the nucleic acid sequence of SEQ ID NO: 18 or an active fragment thereof,

(ix) a reverse primer comprising the nucleic acid sequence of SEQ ID NO: 19 or an active fragment thereof, and

(x) a reverse primer comprising the nucleic acid sequence of SEQ ID NO: 20 or an active fragment thereof,

wherein the forward primers and the reverse primers are deoxyribonucleic acid primers, and wherein an active fragment is 15 or more nucleotides in length.

3. A kit for amplifying a portion of a HCV NS3 1b genomic sequence by nested PCR comprising:

(a) a container comprising a set of inner primers, and

(b) a container comprising a set of outer primers, wherein the set of outer primers consists of the collection of primers of claim 2 .

4. A kit for amplifying a portion of a HCV NS3 1b genomic sequence by nested PCR comprising:

(a) a container comprising a set of inner primers, and

(b) a container comprising a set of outer primers, wherein the set of outer primers consists of the amplification primer pair of claim 1 .

5. The kit of claim 4 , wherein at least some of the inner primers are labeled with a detectable moiety.

6. The kit of claim 4 , wherein at least some of the inner primers are tagged with tag sequences.

7. The kit of claim 6 , wherein the tag sequences are M13 tag sequences.

8. A method of amplifying HCV NS3 in a sample comprising contacting a sample with a set of outer primers, wherein the set of outer primers consists of the amplification primer pair of claim 1 and submitting the resulting mixture to a first nucleic acid amplification reaction.

9. The method of claim 8 , further comprising contacting a product from the first nucleic acid amplification reaction with a set of inner primers and submitting the resulting mixture to a second nucleic acid amplification reaction.

10. The method of claim 9 , wherein at least some of the inner primers are labeled with a detectable moiety.

11. The method of claim 9 , wherein at least some of the inner primers are tagged with tag sequences.

12. The method of claim 11 , wherein the tag sequences are M13 tag sequences.

13. The method of claim 9 , further comprising sequencing a product from the second nucleic acid amplification reaction to detect an HCV NS3 polymorphism.

14. The method of claim 8 , wherein the set of outer primers comprises the collection of primers of claim 2 .

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 1, 2016
From: UZGIRIS, AREJAS; PANDIT, SUNIL; PALMER, LANCE
To: SIEMENS HEALTHCARE DIAGNOSTICS INC.
Reel/Frame 040783/0089 →
Continuity (4)
Division 14127224
Provisional Application 61498870 · Jun 20, 2011
Provisional Application 61645149 · May 10, 2012
Related Publication 20170137901A1 · May 18, 2017